AKT1 and renal carcinoma: In accordance with our data, similar recent findings show that new mTOR kinase inhibitor (WYE-687) increased apoptosis and blocked activation of both mTORC1 and mTORC2 through the feedback activation of p-Akt in renal cancer cells as well as the oral administration of WYE-687 potently suppressed tumor growth in nude mice injected with renal cancer cells [33].